C the attachment-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
Comment
Favorite

Welcome tomorrow
07-25

C the attachment

Viking Therapeutics Shares Surge 28% as Obesity Treatment Moving into Phase 3 Trial

Shares of $Viking Therapeutics$ on Wednesday jumped in post-market trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.The stock was up 19.1%, to $60.04, in pre-market trading on Thursday.The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as

Viking Therapeutics Shares Surge 28% as Obesity Treatment Moving into Phase 3 Trial

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":331315169460392,"tweetId":"331315169460392","gmtCreate":1721895320631,"gmtModify":1721895324736,"author":{"id":4181345597915312,"idStr":"4181345597915312","authorId":4181345597915312,"authorIdStr":"4181345597915312","name":"Welcome tomorrow","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>C the attachment&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>C the attachment&nbsp;</p></body></html>","text":"C the attachment","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/331315169460392","repostId":1101118643,"repostType":2,"repost":{"id":"1101118643","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1721915282,"share":"https://www.laohu8.com/m/news/1101118643?lang=&edition=full","pubTime":"2024-07-25 21:48","market":"us","language":"en","title":"Viking Therapeutics Shares Surge 28% as Obesity Treatment Moving into Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1101118643","media":"Tiger Newspress","summary":"Shares of $Viking Therapeutics$ on Wednesday jumped in post-market trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.The stock was up 19.1%, to $60.04, in pre-market trading on Thursday.The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/VKTX\">Viking Therapeutics</a> jumped in morning trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.</p><p>The stock was up 28.25%, to $64.65, in morning trading on Thursday.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3f45b7d0e7040cae66f2639eb19e71c5\" tg-width=\"754\" tg-height=\"622\"/></p><p>The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.</p><p>The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as promising safety and tolerability.</p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Shares Surge 28% as Obesity Treatment Moving into Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Shares Surge 28% as Obesity Treatment Moving into Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2024-07-25 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/VKTX\">Viking Therapeutics</a> jumped in morning trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.</p><p>The stock was up 28.25%, to $64.65, in morning trading on Thursday.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3f45b7d0e7040cae66f2639eb19e71c5\" tg-width=\"754\" tg-height=\"622\"/></p><p>The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.</p><p>The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as promising safety and tolerability.</p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VKTX":"Viking Therapeutics, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101118643","content_text":"Shares of Viking Therapeutics jumped in morning trading after the company said that its VK2735 drug to tackle obesity is advancing to a phase 3.The stock was up 28.25%, to $64.65, in morning trading on Thursday.The clinical-stage biopharmaceutical company said that its first-half was marked by strong momentum in its pipeline program.The phase 2 Venture study of VK2735 in obesity demonstrated up to an about 15% reduction in body weight following 13 weeks of dosing, as well as promising safety and tolerability.","news_type":1},"isVote":1,"tweetType":1,"viewCount":326,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}